Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 4/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7529821 | 0.98 | RAB9A (0.54) | RAB9ALMNAALDH1A1POLBMAOA | |
| Hydrochloric Acid SCHEMBL1978418 | 0.75 | RAB9A (0.50) | RAB9ALMNAALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL11516807 | 0.75 | RAB9A (0.50) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL4762153 | 0.73 | RAB9A (0.51) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL3441643 | 0.72 | RAB9A (1.00) | RAB9ALMNAALDH1A1POLBDRD2 | |
| Hydrochloric Acid SCHEMBL16038162 | 0.72 | RAB9A (0.50) | RAB9ALMNAALDH1A1POLB | |
| SCHEMBL8992633 | 0.71 | ALDH1A1 (0.50) | RAB9ALMNAALDH1A1POLBKDM4E | |
| Hydrochloric Acid SCHEMBL7526788 | 0.70 | RAB9A (0.97) | RAB9ALMNAALDH1A1POLBDRD2 | |
| SCHEMBL9582051 | 0.70 | RAB9A (0.49) | RAB9ALMNAALDH1A1POLBTSHR | |
| SCHEMBL4357488 | 0.70 | RAB9A (0.74) | RAB9ALMNAALDH1A1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| CN-115260180-B | Triazole condensed ring derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240116930-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-04-11 | — | — | US | disclosed |
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| CN-115260180-A | Triazole fused ring containing derivative, pharmaceutical composition, preparation method and application thereof | 长春金赛药业有限责任公司 | 2022-11-01 | — | — | CN | disclosed |
| US-20220213095-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2022-07-07 | — | — | US | disclosed |
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V. (DE) | 2021-11-30 | — | — | US | disclosed |
| EP-3548613-B1 | BACTERIAL GLUTAMINYL CYCLASE INHIBITORS AND USE THEREOF IN THE TREATMENT OF PERIODONTITIS | FRAUNHOFER GES FORSCHUNG (DE) | 2021-01-27 | — | — | EP | disclosed |
| US-10112937-B2 | P2X7 modulators and methods of use | JANSSEN PHARMACEUTICA NV (BE) | 2018-10-30 | — | — | US | disclosed |
| US-20160039809-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258129-B2 | 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-13 | — | — | US | disclosed |
| EP-2041132-A2 | NEW COMPOUNDS | Boehringer Ingelheim International GmbH (DE) | 2009-04-01 | — | — | EP | disclosed |
| WO-2008003766-A2 | 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-11186572-B2 | Bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis | GMPS, QPCT, GLS | RAB9A 533/4885LMNA 2144/4885ALDH1A1 2706/4885 |
| US-10112937-B2 | P2X7 modulators and methods of use | P2RX2, P2RX7, P2RX5 | RAB9A 3323/4885LMNA 2030/4885ALDH1A1 1385/4885 |
| US-20160039809-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RX5 | RAB9A 3305/4885LMNA 2157/4885ALDH1A1 1381/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-20220213095-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
| US-20090203673-A1 | 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS | CCNI, MKI67, CCNA1 | RAB9A 2108/4885LMNA 731/4885ALDH1A1 293/4885 |
| US-20240116930-A1 | P2X7 MODULATORS | P2RX2, P2RX7, P2RY2 | RAB9A 3242/4885LMNA 2272/4885ALDH1A1 1628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.